Answers are grounded in this paper and cite their sources.
The phosphoinositide-3-kinase-α is a key regulator of tumor progression across different cancers, including triple-negative breast cancer. Herein, we explored thienopyrimidine and pyridofuropyrimidine cores to identify a PI3K-α inhibitor for the treatment of TNBC with favorable ADME properties. Structure-guided drug design and lead optimization efforts led to the identification of piperidine urea analog 50b as a PI3K-α inhibitor, which effectively inhibits the growth of MDA-MB-231 cells by targeting p110α, MAP kinase pathways, enhancing the expression of apoptotic proteins and impeding the cell’s migratory capabilities. Compound 50b occupies the PI3K-α hinge pocket and forms H-bonding with VAL851, as well as with GLN859, a nonconserved residue linked to isoform selectivity. It exhibited a favorable ADME/PK profile, with 56% oral bioavailability, and demonstrated efficacy in the MDA-MB-231 xenograft model at peroral doses ranging from 25 to 75 mg/kg. Acute and repeated-dose toxicity studies confirmed an excellent safety profile, suggesting its potential for further development as a lead molecule for TNBC.
No takes yet. Share an insight, caveat, or question.
Mohammed et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: